These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 15686049

  • 1. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 2. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA, Queiroz RG, Bernardes JE, Valera ET, Tone LG.
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [Abstract] [Full Text] [Related]

  • 3. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Jul; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 4. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J.
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [Abstract] [Full Text] [Related]

  • 5. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, von Stackelberg A, Aleinikova OV.
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [Abstract] [Full Text] [Related]

  • 8. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 9. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
    Levett D, Middleton P, Cole M, Reid MM.
    Med Pediatr Oncol; 2001 Mar 20; 36(3):365-71. PubMed ID: 11241438
    [Abstract] [Full Text] [Related]

  • 10. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 11. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A.
    J Clin Oncol; 2007 Nov 20; 25(33):5254-61. PubMed ID: 18024872
    [Abstract] [Full Text] [Related]

  • 12. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, Otová B, Starý J, Trka J.
    Cancer; 2003 Jan 01; 97(1):105-13. PubMed ID: 12491511
    [Abstract] [Full Text] [Related]

  • 13. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 01; 10(3):333-6. PubMed ID: 18554462
    [Abstract] [Full Text] [Related]

  • 14. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 01; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 15. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW, Liang R, Kwong YL, Chan V.
    Am J Hematol; 1996 Jul 01; 52(3):171-7. PubMed ID: 8756082
    [Abstract] [Full Text] [Related]

  • 16. [Children with acute lymphoblastic leukemia: prognostic significance of polymerase-chain-reaction analysis of minimal residual disease].
    Steenbergen EJ, Verhagen OJ, van den Berg H, van Leeuwen EF, von dem Borne AE, van der Schoot CE.
    Ned Tijdschr Geneeskd; 1996 Jan 06; 140(1):22-8. PubMed ID: 8569906
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology.
    Haematologica; 2002 Feb 06; 87(2):154-66. PubMed ID: 11836166
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E.
    N Engl J Med; 1998 Aug 27; 339(9):591-8. PubMed ID: 9718378
    [Abstract] [Full Text] [Related]

  • 19. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ, Ashton LJ, Kwan E, Norris MD, Haber M, Marshall GM.
    J Clin Oncol; 2005 Apr 01; 23(10):2264-71. PubMed ID: 15800317
    [Abstract] [Full Text] [Related]

  • 20. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H, Mattsson J, Uzunel M, Näsman-Björk I, Svenberg P, Tammik L, Bayat G, Winiarski J, Ringdén O.
    Bone Marrow Transplant; 2000 Apr 01; 25(8):843-51. PubMed ID: 10808205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.